gankyrin Antibody (D-11): sc-373735

gankyrin Antibody (D-11) is a mouse monoclonal IgG3 antibody that detects gankyrin in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Gankyrin is a crucial protein associated with hepatocellular carcinoma, playing a significant role in regulating protein-protein interactions that are vital for cell cycle control and protein degradation. Gankyrin is primarily located in the cytoplasm, where gankyrin interacts with key regulatory proteins such as retinoblastoma protein (Rb) and cyclin-dependent kinase 4 (Cdk4), which are essential for cell cycle progression. This localization allows gankyrin to modulate the activity of these proteins, thereby influencing cellular proliferation and survival. Additionally, gankyrin′s interaction with the 26S proteasome facilitates the targeted degradation of specific proteins, further underscoring gankyrin′s role in maintaining cellular homeostasis. Notably, the interaction between gankyrin and MAGE-A4 has been shown to suppress anchorage-independent growth in cells that overexpress gankyrin, highlighting gankyrin′s potential as a therapeutic target in immunotherapy for hepatocellular carcinoma. anti-gankyrin antibody (D-11) provides a valuable tool for researchers investigating the complex mechanisms of cancer biology and the therapeutic implications of targeting gankyrin in various malignancies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

gankyrin Antibody (D-11) References:

1. Gankyrin promotes the proliferation of human pancreatic cancer.  |  Meng, Y., et al. 2010. Cancer Lett. 297: 9-17. PMID: 20483533
2. Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity.  |  Zhen, C., et al. 2013. Oncogene. 32: 3452-60. PMID: 22890318
3. Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.  |  Kim, YH., et al. 2013. Exp Mol Pathol. 94: 360-5. PMID: 23276718
4. Gankyrin is essential for hypoxia enhanced metastatic potential in breast cancer cells.  |  Gao, L., et al. 2014. Mol Med Rep. 9: 1032-6. PMID: 24337075
5. Interleukin-1β/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis.  |  Su, B., et al. 2015. Hepatology. 61: 585-97. PMID: 25294684
6. Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway.  |  Zhao, X., et al. 2015. Cell Death Dis. 6: e1751. PMID: 25950481
7. Gankyrin activates mTORC1 signaling by accelerating TSC2 degradation in colorectal cancer.  |  Qin, X., et al. 2016. Cancer Lett. 376: 83-94. PMID: 26975632
8. Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell.  |  Chattopadhyay, A., et al. 2016. Sci Rep. 6: 23732. PMID: 27046077
9. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.  |  Liu, R., et al. 2019. Cancer Lett. 443: 34-46. PMID: 30503555
10. The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells.  |  Camacho-Moll, ME., et al. 2019. BMC Cancer. 19: 1124. PMID: 31744479

The preferred gankyrin antibody is gankyrin Antibody (3A6C2): sc-101498.